Status:
COMPLETED
De-implementation of Low-value Pharmacological Prescriptions
Lead Sponsor:
Basque Health Service
Collaborating Sponsors:
Health Department of the Basque Government
Carlos III Health Institute
Conditions:
Inappropriate Prescribing
Implementation Science
Eligibility:
All Genders
Phase:
NA
Brief Summary
The De-imFAR study is a two phase study that aims to carry out and test a structured, evidence-based and theory informed process involving the main stakeholders (managers, professionals, patients and ...
Eligibility Criteria
Inclusion
- Eligibility for professionals:
- FPs belonging to any of the 13 Integrated Healthcare Organizations of Osakidetza
- Non-zero annual incidence rate of PIP of statins at baseline (2021)
- A minimum cluster size of n ≥10 patients
- Eligibility for patients:
- 40- to 74-year-old men and 45- to 74-year-old women
- No history of statin use
- LDL cholesterol levels between 70 and 189 mg/dL and/or TC between 200 and 289 mg/dL
- Without ischemic heart disease/CVD
- Estimated CVR REGICOR \<7.5%
- Attend at least one appointment at the participating FPs' practices during the study period from May 2022 to May 2023, and followed until May 2024
Exclusion
Key Trial Info
Start Date :
May 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 5 2024
Estimated Enrollment :
348 Patients enrolled
Trial Details
Trial ID
NCT04022850
Start Date
May 5 2022
End Date
May 5 2024
Last Update
February 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Primary Care Research Unit of Bizkaia
Bilbao, Bizkaia, Spain, 48014